Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | CASR | P41180 | 4/20 | 0.35 |
| ▸ | ABL1 | P00519 | 6/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.33 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.33 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.33 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | LCK | P06239 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL768889 | 0.86 | CHRM2 (0.39) | HDAC6CHRM2CARM1PRMT6PRMT8 | |
| SCHEMBL769264 | 0.86 | CHRM2 (0.39) | HDAC6CHRM2CARM1PRMT6PRMT8 | |
| SCHEMBL768523 | 0.86 | MCHR1 (0.37) | HDAC6CASRABL1CHRM2MCHR1 | |
| SCHEMBL768358 | 0.86 | HDAC6 (0.38) | HDAC6CHRM2CARM1PRMT6PRMT8 | |
| SCHEMBL380251 | 0.85 | CHRM2 (0.51) | CHRM2 | |
| SCHEMBL768708 | 0.84 | CHRM2 (0.39) | HDAC6CHRM2CARM1PRMT6PRMT8 | |
| SCHEMBL768103 | 0.83 | HRH3 (0.41) | CHRM2CARM1PRMT6 | |
| SCHEMBL768439 | 0.83 | CHRM2 (0.39) | HDAC6CHRM2MCHR1 | |
| SCHEMBL768363 | 0.82 | HRH3 (0.33) | CHRM2CARM1PRMT6PRMT8MCHR1 | |
| SCHEMBL769370 | 0.81 | HDAC6 (0.33) | HDAC6CHRM2MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120071467-A1 | AMIDE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071467-A1 | AMIDE DERIVATIVE | CHRM3, CHRM2, TACR2 | HDAC6 407/4885CASR 737/4885ABL1 3609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.